Thrombin Market Size & Outlook, 2025-2033

Thrombin Market Overview

The global thrombin market size was valued at USD 682.17 million in 2024 and is projected to grow from USD 713.69 million in 2025 to reach USD 1024.30 million by 2033, growing at a CAGR of 4.62% during the forecast period (2025–2033). The global market is driven by the growing incidence of hemophilia and other coagulation disorders, leading to a rising demand for effective hemostatic agents.

Key Market Trends & Insights

• North America held a dominant share of the global market.
• Based on product type, the human thrombin segment holds a significant share of the market.
• Based on form, the powder form segment dominated the market.
• Based on application, the surgical wounds segment dominated the market.
• Based on end-users, the hospitals segment dominates the market.

Market Size & Forecast

• 2024 Market Size: USD 682.17 Million
• 2033 Projected Market Size: USD 1024.30 Million
• CAGR (2025-2033): 4.62%
• North America: Largest market in 2024

The global thrombin market is driven by the increasing volume of surgical procedures worldwide, particularly in trauma, orthopedic, cardiovascular, and neurosurgical fields, where rapid bleeding control is essential. Thrombin’s efficiency in achieving quick hemostasis has also boosted its adoption in minimally invasive surgeries, which are on the rise due to faster recovery times and lower complication risks. In emergency and battlefield medicine, the demand for fast-acting clotting agents further supports market growth.

Additionally, technological advancements in recombinant protein production have enhanced thrombin’s safety and efficacy, reducing risks associated with plasma-derived variants. Furthermore, the aging global population, more susceptible to chronic diseases and surgical interventions, continues to expand the potential patient base. Collectively, these factors are creating sustained demand for thrombin-based products across hospitals, surgical centers, and emergency care settings.

Market Trends

Development of Next-Gen Thrombin Delivery Systems

The global market is witnessing a strong shift toward the development of advanced delivery systems aimed at improving surgical efficiency, safety, and patient outcomes. Manufacturers are focusing on integrating thrombin into innovative formats such as sprayable solutions, prefilled syringes, and bioactive dressings to enable rapid application during complex procedures.

• For instance, in April 2023, Baxter introduced Floseal + Recothrom, the first active flowable hemostat incorporating recombinant thrombin, offering surgeons 1.5× faster preparation compared to the traditional human thrombin version. This represents a meaningful step toward more efficient delivery systems.

Such innovations reduce preparation time, minimize contamination risks, and enhance clotting effectiveness in trauma, cardiovascular, and orthopedic surgeries. The trend is expected to accelerate as surgical demand grows globally, particularly in minimally invasive and emergency procedures.

To get more insights about this report Download Free Sample Report

Market Drivers

Growing Incidence of Hemophilia and Coagulation Disorders

The global market is significantly driven by the increasing prevalence of hemophilia and other coagulation disorders, which creates a rising demand for effective hemostatic agents. Hemophilia, characterized by a deficiency in clotting factors, leads to prolonged bleeding episodes that require advanced therapeutic interventions.

• According to projections from the World Federation of Hemophilia, based on data from established patient registries, approximately 836,000 people worldwide are living with hemophilia, including around 284,000 individuals with severe forms of the condition. Globally, per 100,000 males, 17.1 have hemophilia A, 3.8 have hemophilia B, and 6 and 1.1 severe cases, respectively.

The increasing diagnostic rates, improved patient registries, and awareness programs are further uncovering previously undiagnosed cases, thereby boosting the need for thrombin-based treatments in both surgical and emergency care settings.

Market Restraint

Risk of Allergic Reactions Or Antibody Formation in Some Patients

The risk of allergic reactions or antibody formation remains a significant restraint in the global market. Some patients develop hypersensitivity responses, particularly to plasma-derived thrombin, which may trigger rashes, swelling, or severe anaphylactic reactions. Additionally, repeated exposure can lead to the development of neutralizing antibodies, reducing thrombin’s efficacy in future treatments.

These reactions are more common in individuals with a history of protein-based drug allergies. The concern is amplified in surgical settings where rapid clotting is critical, as adverse immune responses can complicate recovery. Consequently, stringent pre-use testing, cautious patient monitoring, and a shift toward recombinant alternatives are essential to mitigate these clinical and commercial challenges.

Market Opportunities

Expanding Medical Tourism in the Asia-Pacific

The Asia-Pacific region’s robust growth in medical tourism presents a significant opportunity for the global market. Rising surgical procedures in destinations such as Thailand, Malaysia, and India are driving demand for advanced hemostatic agents. Many international patients seek high-quality yet cost-effective treatments, including complex surgeries where thrombin plays a crucial role in controlling bleeding.

• For instance, according to the US-ASEAN Business Council Inc., in 2023, Thailand welcomed 2.86 million medical tourists earning US$850 million in revenue, with arrivals projected to reach 3.07 million in 2024, a 7.3% increase. Malaysia, meanwhile, earned over RM 2 billion (~US$450 million) from international patients in 2023, thanks to its affordable pricing, strong healthcare infrastructure, and focused promotion via the Malaysia Healthcare Travel Council.

This growing influx fuels thrombin adoption in surgical care.

Regional Analysis

The North American market is experiencing steady growth, driven by advanced surgical infrastructure and high adoption of recombinant thrombin in complex procedures. Increasing surgical volumes, particularly in cardiovascular and orthopedic segments, and a strong emphasis on patient safety are fueling demand. Robust investments in biotechnology and product innovation, alongside favorable reimbursement frameworks, are enhancing market penetration. Additionally, heightened awareness of hemostatic products among healthcare providers and rising cases of chronic conditions requiring surgical intervention are reinforcing the region’s leading position in the global market.

U.s. Thrombin Market Trends

• The US market benefits from a high volume of surgeries, over 40 million annually, creating strong demand for rapid hemostatic agents. Leading players like Pfizer and Baxter market advanced recombinant thrombin products for trauma, neurosurgery, and cardiac procedures. The presence of FDA-approved innovations, alongside initiatives by hospitals such as Mayo Clinic to integrate ready-to-use thrombin, is fueling adoption. Rising defense medical applications also contribute to market growth.
• The Canadian thrombin market is driven by rising surgical procedures, especially in the orthopedic and cardiovascular segments. The increasing adoption of recombinant thrombin, such as Recothrom, in hospitals like Toronto General, enhances patient safety by reducing viral transmission risks. Government investments in advanced surgical tools and the country’s aging population are boosting demand, while medical centers in provinces like Ontario and British Columbia are expanding hemostatic product usage.

Asia-Pacific: Significantly Growing Region

Asia Pacific’s market is expanding rapidly due to significant growth in surgical interventions and improved healthcare infrastructure. Rising awareness of advanced hemostatic solutions, coupled with the increasing incidence of trauma and chronic diseases, is accelerating adoption. The region is witnessing growing medical tourism and investment in modern surgical facilities, enhancing accessibility to recombinant thrombin products. Strong economic growth and the development of local biotechnology capabilities are driving product availability. Additionally, training initiatives for surgeons and healthcare providers are helping expand the application of thrombin in diverse surgical specialties.

• The Chinese market for thrombin is expanding rapidly due to the country’s rising surgical procedures and growing adoption of recombinant thrombin. Increasing cardiovascular and orthopedic surgeries, such as joint replacements in aging populations, fuel demand. Companies like Jiangsu Bicheng Biotechnology are enhancing local production. Additionally, government investment in advanced biologics manufacturing is boosting domestic supply, reducing dependence on imports, and supporting the country’s healthcare modernization goals.
• The Indian thrombin industry is witnessing steady growth, driven by rising trauma cases and an increase in surgeries for conditions like cancer and cardiovascular diseases. Growing adoption of topical hemostats in hospitals, along with government-led healthcare initiatives like Ayushman Bharat, supports market penetration. Local pharmaceutical players, such as Bharat Serums and Vaccines, are investing in R&D to produce affordable recombinant thrombin, meeting the country’s cost-sensitive healthcare needs.

Europe: Substantial Potential for Growth

Europe’s market growth is supported by a well-established healthcare system and early adoption of novel hemostatic technologies. The region benefits from strong regulatory frameworks that encourage quality and safety in surgical products, boosting trust in recombinant thrombin. The increasing geriatric population, coupled with the rise of surgical procedures for orthopedic, cardiovascular, and trauma cases, is driving usage. Growing focus on minimally invasive surgeries and hospital preparedness for emergency care further strengthens demand. Collaborative research between academic institutions and medical device companies is also promoting innovative thrombin applications in clinical practice.

• Germany’s market is driven by its advanced surgical infrastructure and strong biotechnology sector. The rising number of orthopedic and cardiovascular surgeries in hospitals like Charité – Universitätsmedizin Berlin fuels demand for recombinant thrombin. Germany’s aging population and focus on minimally invasive procedures boost adoption. Companies such as Baxter and Pfizer collaborate with German clinics to expand thrombin-based hemostatic solutions, particularly in trauma and emergency care.
• The UK’s thrombin industry benefits from the country’s well-established NHS surgical network and growing demand for effective hemostatic agents in cardiovascular and orthopedic operations. Increased adoption of recombinant thrombin in hospitals such as St. Thomas’ is driven by its safety profile and quick clotting action. Government investments in medical innovation and clinical trials support market growth, with firms like Johnson & Johnson enhancing product accessibility.

Market Segmentation

Product Type Insights

The human thrombin segment holds a significant share in the global market due to its high biocompatibility and reduced risk of immunogenic reactions compared to bovine-derived products. Sourced from human plasma, it is widely used in complex surgeries where precision in hemostasis is crucial. Its clinical effectiveness in controlling bleeding during cardiovascular, neurosurgical, and orthopedic procedures drives its demand. Additionally, advancements in purification techniques and strict quality control measures enhance its safety profile, further boosting its adoption across developed healthcare markets.

Dosage Form Insights

The powder form segment is a dominant category in the global market owing to its extended shelf life, ease of storage, and stable composition. It can be quickly reconstituted before use, making it highly suitable for both planned surgeries and emergency medical situations. Powder thrombin is extensively utilized in operating rooms for topical application to control bleeding in surgical wounds and trauma cases. Its portability and compatibility with various surgical tools enhance its preference among healthcare professionals across hospitals and surgical centers.

Application Insights

The surgical wounds segment accounts for a major share of the market, as thrombin plays a vital role in achieving rapid hemostasis during and after surgery. It is widely applied in cardiovascular, orthopedic, and general surgeries to minimize blood loss and accelerate wound healing. Thrombin’s efficiency in promoting clot formation makes it an essential hemostatic agent for complex surgical interventions. Increasing global surgical volumes and advancements in wound management techniques further support the growth of this segment.

End-User Insights

Hospitals represent the largest end-user segment in the global market due to the high volume of surgical procedures conducted in these facilities. They extensively utilize thrombin in diverse specialties, including trauma care, neurosurgery, orthopedic surgery, and cardiovascular operations. Hospitals benefit from in-house surgical teams and advanced equipment, enabling efficient use of thrombin-based hemostatic solutions. The increasing number of hospital-based surgeries, coupled with the rising demand for recombinant and human-derived thrombin products, strengthens the dominance of this segment in the market.

Company Market Share

In the global market, companies are focusing on expanding their portfolios through advanced recombinant technologies, enhancing product safety and efficacy. They are investing in R&D for innovative delivery forms like sprays, gels, and patches, targeting minimally invasive procedures. Strategic partnerships with healthcare providers, regulatory approvals for new formulations, and expansion into emerging markets are key growth tactics. Additionally, firms are improving manufacturing scalability to meet rising global surgical demand.

Johnson & Johnson Services, Inc.: Johnson & Johnson Services, Inc. is a major player in the global thrombin market through its medical devices segment, particularly under Ethicon, which offers advanced surgical hemostatic products. The company provides thrombin-based solutions to control bleeding in diverse surgical procedures, leveraging strong R&D capabilities and a global distribution network. Its extensive presence in hospitals worldwide, commitment to innovation, and acquisitions in surgical care technologies strengthen its competitive position. Johnson & Johnson’s brand trust and regulatory compliance further support its dominance in the market.

• In March 2025, Johnson & Johnson is significantly ramping up its U.S. presence with a $55 billion investment over the next four years to boost manufacturing, R&D, and technology, including a new biologics facility in North Carolina, addressing areas like oncology, immunology, neuroscience, cardiovascular disease, and robotic surgery.

List of key players in Thrombin Market

1. Pfizer Inc.
2. Johnson & Johnson Services, Inc.
3. Baxter International Inc.
4. Grifols S.A.
5. Mochida Pharmaceutical Co., Ltd.
6. Shanghai RAAS Blood Products Co., Ltd.
7. BIOFAC A/S
8. Merck KGaA
9. Valiant Co., Ltd.

To get more findings about this report Download Market Share

Recent Developments

• July 2025- Stryker officially launched the Surpass Elite® Flow Diverter in the U.S., South Korea, and Europe. This advanced neurovascular implant features a novel BioStealth surface treatment that enhances thromboresistance, thereby reducing thrombin generation risk during vascular procedures.
• February 2025- QUALIblood and Diagnostica Stago entered a strategic partnership to develop and prepare for the launch of nAPCsr, a thrombin generation test. This diagnostic kit is designed to assess thrombosis risk, particularly for women considering or using estrogen-based hormonal treatments, such as oral contraceptives.